Apyx Medical Corp (APYX) Skyrockets 52% on FDA Granting Clearance

Apyx Medical Corp (APYX) shot up around 52% on news that the FDA granted clearance for the use of its Renuvion cosmetic technology in certain dermal resurfacing procedures.

Renuvion is indicated for the treatment of moderate to severe wrinkles and rhytides in patients with Fitzpatrick skin types I, II or III, according to the Company.

“We are very pleased to receive FDA 510(k) clearance with a specific clinical indication that enables Apyx Medical to market and sell our Renuvion Cosmetic Technology to surgeons and patients for use in approximately 200,000 wrinkle reduction procedures performed in the U.S. annually,” said Charlie Goodwin, President and Chief Executive Officer. “This milestone represents one of the most important achievements of our organization since we began our multi-year strategy to position Apyx Medical for long-term success in the U.S. cosmetic surgery market, and I would like to thank our clinical and regulatory teams for making it possible. The receipt of regulatory clearance reflects the strong safety and efficacy profile of our Renuvion Cosmetic Technology, as demonstrated by the results of our U.S. IDE clinical study published in February.”

About Apyx Medical Corporation:

Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® and J-Plasma® in surgical markets. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com.

 

Share This Article

 

About the Author

Apyx Medical Corp (APYX) Skyrockets 52% on FDA Granting Clearance

Editor Prism MarketView